SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mitsiades, N. Articles by Anderson, K. C. Search for Related Content PubMed PubMed Citation Articles by Mitsiades, N. Articles by Anderson, K. C. Related Collections Neoplasia Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 June 2002, Vol. 99, No. 11, pp. 4079-4086 NEOPLASIA Biologic sequelae of nuclear factor-B blockade in multiple myeloma: therapeutic applications Nicholas Mitsiades, Constantine S. Mitsiades, Vassiliki Poulaki, Dharminder Chauhan, Paul G. Richardson, Teru Hideshima, Nikhil Munshi, Steven P. Treon, and Kenneth C. Anderson From the Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School; the Department of Medicine, Harvard Medical School; and the Retina Research Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA.     Abstract Top Abstract Introduction Materials and methods Results Discussion References The transcription factor nuclear factor-B (NF-B) confers significant survival potential in a variety of tumors. Several established or novel anti-multiple myeloma (anti-MM) agents, such as dexamethasone, thalidomide, and proteasome inhibitors (PS-341), inhibit NF-B activity as part of their diverse actions. However, studies to date have not delineated the effects of specific inhibition of NF-B activity in MM. We therefore investigated the effect of SN50, a cell-permeable specific inhibitor of NF-B nuclear translocation and activity, on MM cells. SN50 induced apoptosis in MM cell lines and patient cells; down-regulated expression of Bcl-2, A1, X-chromosome-linked inhibitor-of-apoptosis protein (XIAP), cellular inhibitor-of-apoptosis protein 1 (cIAP-1), cIAP-2, and survivin; up-regulated Bax; increased mitochondrial cytochrome c release into the cytoplasm; and activated caspase-9 and caspase-3, but not caspase-8. We have previously demonstrated that tumor necrosis factor- (TNF-) is present locally in the bone marrow microenvironment and induces NF-B-dependent up-regulation of adhesion molecules on both MM cells and bone marrow stromal cells, with resultant increased adhesion. In this study, TNF- alone induced NF-B nuclear translocation, cIAP-1 and cIAP-2 up-regulation, and MM cell proliferation; in contrast, SN50 pretreatment sensitized MM cells to TNF--induced apoptosis and cleavage of caspase-8 and caspase-3, similar to our previous finding of SN50-induced sensitization to apoptosis induced by the TNF- family member TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L. Moreover, SN50 inhibited TNF--induced expression of another NF-B target gene, intercellular adhesion molecule-1. Although the p38 inhibitor PD169316 did not directly kill MM cells, it potentiated the apoptotic effect of SN50, suggesting an interaction between the p38 and NF-B pathways. Our results therefore demonstrate that NF-B activity in MM cells promotes tumor-cell survival and protects against apoptotic stimuli. These studies provide the framework for targeting NF-B activity in novel biologically based therapies for MM. (Blood. 2002;99:4079-4086) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Multiple myeloma (MM), a presently incurable B-cell malignancy, affects 14 000 new patients in the United States annually and is the second most common hematologic malignancy.1-3 Combination chemotherapy offers initial response rates of 40% to 70% in MM patients,4 but refractoriness to these regimens eventually develops. High-dose chemotherapy with stem cell support has achieved higher response rates than conventional therapy, but few patients remain in long-term remission, highlighting the urgent need for novel therapeutic strategies. The Rel/nuclear factor-B (Rel/NF-B) proteins comprise a family of transcription factors, which is conserved from Drosophila to humans and regulates a variety of physiological aspects of immune and inflammatory responses. These proteins bind to 10 base pair DNA sites (B sites) as dimers and directly regulate gene transcription. NF-B commonly refers to the p50-RelA heterodimer, which is the major Rel complex. In most cell types, NF-B is present constitutively in the cytosol in a latent, inactive form where it is retained through its interaction with inhibitory IB (inhibitor of NF-B) proteins, masking its nuclear localization sequence. A variety of stimuli induce phosphorylation of IB at 2 N-terminal Ser residues by the IB kinase complex, followed by ubiquitination and degradation of IB by the proteasome.5 Rel/NF-B complex then enters the nucleus, binds to DNA, and activates transcription of target genes whose products include proteins mediating host immune responses, such as cytokines, chemokines, major histocompatibility complex molecules; proteins involved in antigen presentation; and receptors required for neutrophil adhesion and transmigration across blood vessel walls.5 NF-B was originally identified as a B-cell nuclear factor, and NF-B activity is required for proper regulation of B-cell homeostasis.6,7 Constitutive NF-B activity is also present in some neurons,8 human thymocytes,9 Sertoli cells,10 and photoreceptor cells.11 Members of the NF-B/Rel transcription-factor family are expressed constitutively during B-cell development, and they are further induced by mitogen activation.12 Conversely, activated B cells from mice harboring germline disruptions in individual NF-B subunits exhibit increased sensitivity to apoptosis.13 There is also accumulating evidence that many tumor cells have constitutive NF-B site-binding and transactivation activity.14-17 Consequently, NF-B has emerged as a therapeutic target in a variety of neoplasias. For example, NF-B is constitutively activated in primitive human acute myelogenous leukemia cells, and the proteasome inhibitor MG-132 inhibits IB degradation and induces tumor cell apoptosis.18,19 Rel/NF-B activity inhibits apoptosis in WEHI 231 immature B-lymphoma cells, whereas treatment with inhibitors of NF-B induction, including the proteasome inhibitor N-tosyl-L-phenylalanine chloromethyl ketone and microinjection of glutathione-S-transferase-IB or an antibody to c-Rel, sensitizes these cells to anti-immunoglobulin M (anti-IgM)-induced apoptosis.20 The importance of NF-B activity for survival of activated B cells, coupled with the constitutive activity of NF-B in several malignancies, prompted us to investigate its role in MM pathophysiology. Moreover, several conventional or emerging anti-MM agents, such as dexamethasone, proteasome inhibitors, and thalidomide, possess anti-NF-B activity.21-26 To date, however, the direct effects of specific NF-B inhibition have not been studied in MM. We therefore evaluated the effects of SN50, a cell-permeable peptide that specifically inhibits NF-B nuclear transport and activity, in MM cell lines and patient cells. As tumor necrosis factor- (TNF-) is secreted into the bone marrow microenvironment27 and confers resistance to MM cell apoptosis, we also investigated the effects of NF-B inhibition on TNF--induced signaling. Our studies demonstrate that NF-B activity promotes growth, survival, and drug resistance in MM cells and that these effects can be inhibited by NF-B blockade. Importantly, they provide the framework for novel therapies targeting NF-B in MM.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References MM cell lines and MM patient cells Dexamethasone-sensitive MM.1S and dexamethasone-resistant MM.1R human MM cell lines were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL). RPMI-8226/S cells and its doxorubicin-resistant subline (Dox40) were a kind gift from Dr William Dalton (Lee Moffit Cancer Center, Tampa, FL). OCI-My5 cells were kindly provided by Dr H. A. Messner (Ontario Cancer Institute, Toronto, Ontario, Canada). ARH-77, HS-Sultan, and IM-9 Epstein-Barr virus (EBV)-transformed B-cell lines were obtained from the American Type Culture Collection (Manassas, VA). The MM-AS cell line has been established from an MM patient sample.28 Malignant plasma cells were freshly isolated from peripheral blood of a patient with plasma cell leukemia and were confirmed by flow cytometric analysis to be greater than 95% CD38+CD45RA. All cells were cultured in RPMI 1640 medium (GIBCO Laboratories, Grand Island NY) supplemented with 10% charcoal dextran-treated fetal bovine serum (Hyclone, Logan, UT) as well as L-glutamine, penicillin, and streptomycin (GIBCO). Materials The peptide SN50, consisting of the nuclear localization sequence of p50 (residues 360 to 369) fused to the hydrophobic region of the signal sequence of Kaposi fibroblast growth factor to provide cell permeability, specifically inhibits nuclear translocation of NF-B.29-36 SN50M, a synthetic analog with a mutated nuclear localization sequence, is inactive and served as a negative control.29 Both peptides were purchased from BIOMOL (Plymouth Meeting, PA). TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L was provided by Genentech (South San Francisco, CA) and PS-341 by Millennium (Cambridge, MA). Other reagents were obtained as follows: p38 inhibitor PD169316 (Calbiochem, La Jolla, CA); mouse monoclonal antibodies for Bcl-2, BclxL, A1, Bax, and tubulin and polyclonal antibody for Mcl-1 (Santa Cruz Biotechnology, Santa Cruz, CA); human recombinant interleukin-6 (IL-6) and polyclonal antisera against cellular inhibitor-of-apoptosis protein 1 (cIAP-1), cIAP-2, and X-chromosome-linked IAP (XIAP) (R&D Systems, Minneapolis, MN); polyclonal antiserum against survivin (Oncogene Research, Cambridge, MA); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dexamethasone, and doxorubicin (Sigma Chemical, St Louis, MO); a Complete (proprietary name) mixture of proteinase inhibitors, immunoglobulin-free normal horse serum and sodium dodecyl sulfate (SDS) (Life Technologies, Gaithersburg, MD); and the Enhanced Chemiluminescence (ECL) kit, which includes the peroxidase-labeled antimouse and antirabbit secondary antibodies (Amersham, Arlington Heights, IL). Evaluation of NF-B activity The DNA-binding activity of NF-B in MM.1S cells was quantified by enzyme linked immunosorbent assay (ELISA) by means of the Trans-AM NF-B p65 Transcription Factor Assay Kit (Active Motif North America, Carlsbad, CA), according to the manufacturer's instructions. Briefly, MM.1S cells were cultured with or without SN50 (20 µM) for 1 hour, and then treated with or without TNF- (50 ng/mL) for 4 hours. Nuclear extracts were prepared as previously described37 and incubated in 96-well plates coated with immobilized oligonucleotide (5'-AGTTGAGGGGACTTTCCCAGGC-3') containing a consensus (5'-GGGACTTTCC-3') binding site for the p65 subunit of NF-B. NF-B binding to the target oligonucleotide was detected by incubation with primary antibody specific for the activated form of p65 (Active Motif North America), visualized by anti-IgG horseradish peroxidase conjugate and developing solution, and quantified at 450 nm with a reference wavelength of 655 nm. Background binding, obtained by incubation with a 2-nucleotide mutant oligonucleotide (5'-AGTTGAGGCCACTTTCCCAGGC-3'), was subtracted from the value obtained for binding to the consensus DNA sequence. MTT colorimetric survival assay The survival of MM cells was examined by means of the MTT colorimetric assay, as previously described.38 Cells were plated in 48-well plates at 70% to 80% confluence and then incubated for 18 hours with the indicated concentration of SN50. At the end of each treatment, cells were incubated with 1 mg/mL MTT for 4 hours at 37°C; a mixture of isopropanol and 1N HCl (23:2, vol/vol) was then added under vigorous pipetting to dissolve the formazan crystals. Dye absorbance in viable cells was measured at 570 nm, with 630 nm as a reference wavelength. Cell survival was estimated as a percentage of the value of untreated controls. All experiments were repeated at least 3 times, and each experimental condition was repeated in at least quadruplicate wells in each experiment. Annexin V-propidium iodide staining Detection of early apoptotic cells was performed by means of the annexin V-propidium iodide (PI) detection kit (Immunotech/Beckman Coulter, Miami, FL). Briefly, 106 MM cells were exposed for 4 hours to SN50 (20 M), washed with Dulbecco modified Eagle medium, incubated in the dark at 4°C with annexin V-fluorescein isothiocyanate (annexin V-FITC) and PI for 15 minutes, and then analyzed by dual-color flow cytometry. Cells that were annexin V-FITC-positive (with translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane) and PI-negative (with intact cellular membrane) were considered early apoptotic cells. In another experiment, MM cells were preincubated with caspase inhibitors (pan-caspase inhibitor ZVAD-FMK, caspase-8 inhibitor IETD-FMK, caspase-3 inhibitor DEVD-FMK, and caspase-9 inhibitor LEHD-FMK; all used at 20 µM) for 1 hour prior to exposure to SN50 (20 µM). Immunoblotting analysis Immunoblotting analysis was performed as previously described.38 Briefly, cells were lysed for 30 minutes on ice in lysis buffer (50 mM Tris-HCl, pH 8, with 120 mM NaCl and 1% NP-40) supplemented with the Complete mixture of proteinase inhibitors. The samples were cleared by microcentrifugation (14 000 rpm, 30 minutes, 4°C) and assessed for protein concentration. We electrophoresed 30 µg protein per sample in a 12% SDS-polyacrylamide gel and electroblotted it onto nitrocellulose membranes. After 1-hour incubation in blocking solution (20% IgG-free normal horse serum, in phosphate-buffered saline [PBS]), the membranes were exposed overnight at 4°C to the primary antibody. Following washing in PBS, the respective secondary peroxidase-labeled antibody was applied at 1:10 000 dilution for 1 hour at room temperature. The proteins were visualized with the ECL technique. Subcellular fractionation and cytochrome c detection MM.1S cells were treated with or without SN50 (20 µM) for 4 hours, washed in cold PBS once, harvested in 100 µL isotonic buffer (210 mM mannitol, 70 mM sucrose, 1 mM EDTA, and 10 mM Hepes, pH 7.5, supplemented with the Complete protease inhibitors cocktail) and homogenized with a Dounce homogenizer. Samples were centrifuged originally at 1000g to remove the nuclei, and subsequently at 10 000g for 30 minutes at 4°C to obtain the heavy membrane, mitochondria-enriched pellet. Both the mitochondria-enriched and the cytoplasm-enriched supernatant were assayed for the presence of cytochrome c by means of an ELISA,39 according to the manufacturer's instructions (R&D Systems). Cleavage of caspases and poly(ADP-ribose) polymerase The involvement of caspases in SN50-induced apoptosis in MM cells was studied by evaluating the levels of procaspase-8, procaspase-3, and procaspase-9, as well as the emergence of their cleaved active forms, by immunoblotting in lysates of cells treated with SN50 (20 µM) for 4, 8, and 16 hours. The cleavage of poly(ADP-ribose) polymerase (PARP), a well-known target of caspase activity, was also studied in the same lysates. Treatment with TRAIL/Apo2L served as a positive control for caspase activation, as previously reported.40 Statistical analysis Statistical significance was examined by a 2-way analysis of variance, followed by a Duncan post hoc test. In all analyses, P < .05 was considered statistically significant.     Results Top Abstract Introduction Materials and methods Results Discussion References SN50 down-regulates constitutive and induced NF-B activity in MM.1S We first evaluated the ways in which the DNA-binding activity of NF-B in MM cells was affected by SN50, a cell-permeable peptide derived from the nuclear localization sequence of p50, which inhibits the nuclear translocation of NF-B.9,30 As seen in Figure 1, constitutive NF-B DNA-binding activity in MM.1S cells was significantly inhibited by SN50. Moreover, SN50 also inhibited NF-B activation induced by TNF. View larger version (10K): [in this window] [in a new window]   Figure 1. Effect of SN50 on NF-B activity in MM cells. SN50 down-regulates constitutive and induced NF-B activity in MM cells. DNA-binding activity of the transcriptional factor NF-B was quantified in MM.1S cells pretreated with or without SN50 (20 µM) for 1 hour, and then treated with or without TNF- (50 ng/mL) for 4 hours. The DNA binding activity of NF-B in MM.1S cells was quantified by ELISA with the use of the Trans-AM NF-B p65 Transcription Factor Assay Kit, according to the manufacturer's instructions. Values (mean ± SD) were normalized for cellular protein content. Data are representative of 3 experiments. Constitutive NF-B DNA-binding activity in MM.1S cells was significantly inhibited by SN50. Moreover, SN50 inhibited NF-B activation induced by TNF-. SN50 induces apoptosis in MM cells We next investigated the effect of SN50 on MM cell survival by means of the MTT assay. As can be seen in Figure 2A-B, SN50 induced concentration-dependent cell death in 7 of 9 cell lines, including MM cell lines resistant to dexamethasone or doxorubicin, EBV-transformed ARH-77 and IM-9 cells, and freshly isolated patient MM cells. In contrast, normal peripheral B cells were resistant to SN50-induced cell death. Annexin V-PI labeling revealed early externalization of phosphatidylserine in MM.1S cells treated with SN50 for 5 hours (Figure 2C-D), confirming that SN50 induced apoptosis. Mutation of 2 amino-acid residues in SN50, which results in loss of its NF-B inhibitory activity, also abolished its anti-MM activity (Figure 2E). View larger version (21K): [in this window] [in a new window]   Figure 2. Effect of NF-B inhibition on apoptosis in MM cells. NF-B inhibition induces apoptosis in MM cells. (A) (B) Dose-response survival curves based on MTT colorimetric assay were generated for MM cells and healthy donor B cells cultured for 18 hours with SN50 (0 to 25 µM). Data shown (absorbance at 570 nm, mean ± SD) are representative of 3 experiments. Panel A shows dexamethasone-sensitive MM.1S () and dexamethasone-resistant MM.1R () cells; RPMI-8226/S () and its cytotoxic drug-resistant subline Dox40 (filled diamond) cells; and OCI-My5 () and MM-AS () cells. Panel B shows EBV-transformed ARH-77 () cells, HS Sultan () cells, and IM-9 () cells; freshly isolated patient MM cells (); and healthy donor peripheral blood B cells (filled diamond). SN50 induced concentration-dependent cell death in 7 of 9 cell lines, including MM cell lines resistant to dexamethasone or doxorubicin, as well as in freshly isolated patient MM cells. In contrast, normal peripheral B cells were resistant to SN50-induced cell death. (C) (D) Annexin-PI staining of MM.1S cells cultured without (panel C) or with (panel D) SN50 (20 µM) for 4 hours revealed early externalization of phosphatidylserine in MM.1S cells treated with SN50 for 5 hours, confirming that SN50 induced apoptosis. (E) The proapoptotic activity of the NF-B inhibitor SN50 () was compared with its mutant (2 amino-acid residue difference), inactive analog SN50M () in MM.1S cells. Data shown (absorbance at 570 nm, mean ± SD) are representative of 3 experiments. Loss of NF-B inhibitory activity abolishes anti-MM activity. SN50 decreases expression of apoptosis inhibitors Having demonstrated that NF-B inhibition with SN50 induces MM cell apoptosis, we next evaluated its effect on the level of protein expression of several apoptosis inhibitors. As can be seen in Figure 3, SN50 rapidly decreased protein expression of Bcl-2, A1, XIAP, cIAP-1, cIAP-2, and survivin. In contrast, Mcl-1 and BclxL protein levels were not changed. Moreover, we found that SN50 up-regulated the expression of the proapoptotic Bax protein. View larger version (32K): [in this window] [in a new window]   Figure 3. Effect of NF-B inhibition on expression of apoptosis inhibitors. NF-B inhibition decreases expression of apoptosis inhibitors. Immunoblotting analysis for apoptosis regulators in cell lysates of MM.1S cells treated with SN50 (20 µM) for 0, 4, 8, or 16 hours. SN50 rapidly decreased protein expression of Bcl-2, A1, XIAP, cIAP-1, cIAP-2, and survivin. In contrast, Mcl-1 and BclxL protein levels were not changed. Moreover, SN50 up-regulated the expression of the proapoptotic Bax protein. SN50 induces cytochrome c release from the mitochondria to the cytoplasm The above-mentioned effects of NF-B inhibition on Bcl-2 family member expression (ie, increase of the proapoptotic Bax and decrease of the antiapoptotic Bcl-2 and A1 proteins) suggested that mitochondrial events could participate in the resulting induction of apoptosis. A major mechanism of mitochondrial regulation of apoptosis is via release of cytochrome c into the cytoplasm. We therefore assayed for cytochrome c in the cytoplasmic and mitochondrial fractions in MM.1S cells before and after treatment with SN50. As can be seen in Figure 4, treatment with SN50 induced a rapid decrease of cytochrome c in the mitochondrial fraction of MM.1S cells, associated with an increase of cytochrome c in the cytosolic fraction. These data suggest that cytochrome c release is associated with MM cell apoptosis induced by NF-B inhibition. View larger version (12K): [in this window] [in a new window]   Figure 4. Effect of NF-B inhibition on cytochrome c release from the mitochondria to the cytoplasm. NF-B inhibition induces cytochrome c release from the mitochondria to the cytoplasm. Cytochrome c protein levels (nanograms per microgram of total protein, mean ± SD) were measured in the cytoplasmic and mitochondrial fractions of MM.1S cells treated with (white bars) or without (black bars) SN50 (20 µM) for 4 hours. Treatment with SN50 induced a rapid decrease of cytochrome c in the mitochondrial fraction of MM.1S cells, associated with an increase of cytochrome c in the cytosolic fraction. Activation of caspases by SN50 We next investigated the potential involvement of downstream caspases mediating SN50-induced MM cell apoptosis. As seen in Figure 5A, treatment with SN50 induced cleavage of caspase-9, caspase-3, and PARP. In contrast, no cleavage of caspase-8 was detected upon SN50 treatment. TRAIL/Apo2L (300 ng/mL for 5 hours) induced caspase-8 cleavage, as in our prior study,40 and served as a positive control. To evaluate the functional involvement of caspases in SN50-induced apoptosis, we used specific inhibitors of caspase-3, caspase-8, and caspase-9. The caspase-9 inhibitor LEHD-FMK and the caspase-3 inhibitor DEVD-FMK partially blocked SN50-induced cell death, whereas the caspase-8 inhibitor IETD-FMK had no effect (Figure 5B). These data collectively suggest that SN50-induced apoptosis is mediated by the mitochondrial release of cytochrome c, triggering activation of caspase-9 and consequent caspase-3 activation. Caspase-8 is not involved, suggesting a mechanism distinct from death-receptor-induced cell death. View larger version (25K): [in this window] [in a new window]   Figure 5. Activation of caspases by NF-B inhibition. (A) Immunoblotting analysis for caspase-9, caspase-3, and caspase-8, as well as PARP, was performed in lysates of MM.1S cells treated with SN50 (20 µM) for 0, 4, 8, or 16 hours. Treatment with SN50 induced cleavage of caspase-9, caspase-3, and PARP. In contrast, no cleavage of caspase-8 was detected upon SN50 treatment. TRAIL/Apo2L (300 ng/mL for 5 hours) induced caspase-8 cleavage, as in our prior studies,40 and served as a positive control. (B) Annexin V-PI staining was performed to quantify phosphatidylserine externalization in MM.1S cells treated with or without SN50 (20 µM) for 4 hours, in the presence or absence of specific inhibitors for caspase-3, caspase-8, and caspase-9. The caspase-9 inhibitor LEHD-FMK and the caspase-3 inhibitor DEVD-FMK partially blocked SN50-induced cell death, whereas the caspase-8 inhibitor IETD-FMK had no effect. SN50 inhibits the stimulatory effect of IL-6 on MM.1S cells Since IL-6 is a major growth factor for MM cells, we next evaluated the impact of SN50 on the stimulatory effect of IL-6 on MM cells. As seen in Figure 6A, IL-6 (50 ng/mL) increased the number of MM.1S cells (approximately 20% after 16 hours), whereas preincubation with SN50 (20 µM) abolished this effect. Moreover, our data demonstrate that IL-6 does not protect against SN50-induced cell death (Figure 6B), suggesting that NF-B inhibition is not attenuated by IL-6. View larger version (8K): [in this window] [in a new window]   Figure 6. Effect of NF-B inhibition on the stimulatory effect of IL-6 on MM.1S cells. NF-B inhibition inhibits the stimulatory effect of IL-6 on MM.1S cells. SN50 overcomes IL-6-induced growth, as evidenced by MTT (panel A), and protection against apoptosis, as evidenced by PI staining (panel B), in MM.1S cells. Data shown (panel A, absorbance at 570 nm, mean ± SD) are representative of 3 experiments. Effect of SN50 on TNF-induced sequelae on MM cells We have previously reported a small, but reproducible, stimulatory effect of TNF- on MM cell proliferation.27 Here, we investigated the effect of NF-B blockade on this response of MM cells to TNF-. In MM.1S cells pretreated with a nontoxic concentration of SN50, TNF- induced decreased, rather than increased, cell growth (Figure 7A). This decreased viability was due to MM cell apoptosis, as evidenced by cleavage and activation of caspase-8 and downstream caspase-3 (Figure 7B). This ability of TNF- to trigger death-receptor-mediated apoptosis in SN50-pretreated MM.1S cells was associated with down-regulation of expression of cIAP-1 and cIAP-2 caspase-8 inhibitory proteins. In contrast, TNF- alone up-regulated cIAP-1 and cIAP-2 expression. These data confirm that TNF- activates a proapoptotic pathway, via caspase-8 activation, as well as an antiapoptotic pathway, via NF-B activation and up-regulation of cIAP-1 and cIAP-2, in MM cells. Our data further suggest that the balance between these 2 pathways is modulated by the level of NF-B activation. Finally, we have also recently reported that the expression of another known NF-B target, intercellular adhesion molecule-1 (ICAM-1), is up-regulated by TNF-.27 As seen in Figure 7B, SN50 strongly inhibits this induction of ICAM-1 on MM.1S cells by TNF-, further implicating NF-B in the regulation of MM cell adhesion and interactions of MM cells in the bone marrow microenvironment. View larger version (21K): [in this window] [in a new window]   Figure 7. Effect of NF-B activity on TNF--induced signaling. TNF--induced signaling is modulated by the activity of NF-B. (A) Cell viability (mean ± SD) was assayed by MTT in MM.1S cells treated with or without TNF- (50 ng/mL), in the presence or absence of SN50 (10 µM) for 18 hours. Data shown (absorbance at 570 nm, mean ± SD) are representative of 3 experiments. In MM.1S cells pretreated with SN50, TNF- induced apoptosis, rather than cell growth. (B) This was evidenced by cleavage and activation of caspase-8 and downstream caspase-3 and was associated with down-regulation of expression of the caspase-8 inhibitory proteins cIAP-1 and cIAP-2 In contrast, TNF- alone up-regulated cIAP-1 and cIAP-2 expression. Moreover, TNF- up-regulated adhesion molecule intercellular adhesion molecule-1 (ICAM-1) expression, and SN50 blocked this effect. The p38 inhibitor PD169316 sensitizes MM.1S cells to apoptosis induced by SN50 Since p38 kinase signaling regulates cell survival41 and the activation of NF-B,42 we next investigated the role of p38 in SN50-induced MM cell apoptosis. The p38 inhibitor PD169316 did not induce MM cell apoptosis, but did enhance the apoptotic effect of SN50, suggesting an interaction between the p38 and NF-B pathways (Figure 8). View larger version (12K): [in this window] [in a new window]   Figure 8. Effect of PD169316 on MM.1S-cell apoptosis induced by NF-B inhibition. The p38 inhibitor PD169316 sensitizes MM.1S cells to apoptosis induced by NF-B inhibition. Cell death was assayed by MTT in MM.1S cells treated with a nontoxic concentration of the p38 inhibitor PD169316 (10 µM) and/or the NF-B inhibitor SN50 (10 µM) for 18 hours. PD169316 did not induce MM cell apoptosis, but did enhance the apoptotic effect of SN50, suggesting an interaction between the p38 and NF-B pathways. Data shown (mean ± SD) are representative of 3 experiments. SN50 sensitizes MM cells to chemotherapy The transcription factor NF-B has been implicated in the regulation of cell sensitivity to chemotherapy in multiple model systems.43,44 We therefore investigated the effect of SN50 on chemotherapy-induced apoptosis in MM.1S cells. As seen in Figure 9A, preincubation with a nontoxic concentration of the NF-B inhibitor SN50 sensitized MM.1S cells to low concentrations of doxorubicin, with the percentage of MM cell survival as follows: 101.6% ± 1.9% with doxorubicin (25 ng/mL) versus 52.1% ± 0.2% with doxorubicin (25 ng/mL) plus SN50 (P < .016); 55.6% ± 4.0% with doxorubicin (50 ng/mL) versus 27.0% ± 1.4% with doxorubicin (50 ng/mL) plus SN50 (P < .005). These data suggest that inhibition of NF-B strongly potentiates the anticancer effects of traditional anti-MM chemotherapy. We also evaluated the combined effects of SN50 with dexamethasone and the proteasome inhibitor PS-341 and found a modest potentiating effect (Figure 9B). View larger version (17K): [in this window] [in a new window]   Figure 9. Effects of NF-B inhibition combined with anti-MM agents. (A) MM.1S cells were incubated with or without doxorubicin (doxo; 25 and 50 ng/mL). At 24 hours later, the cells were treated with or without the NF-B inhibitor SN50 (10 µM) for 18 hours. Cell survival was assayed by MTT. Data shown (mean ± SD) are representative of 3 experiments. The NF-B inhibitor strongly sensitized MM.1S cells to doxorubicin. (B) SN50 (10 µM) also increased, but to a lesser extent, the anti-MM effect of the proteasome inhibitor PS-341 (5 nM, 18 hours), and dexamethasone (dex; 1 µM, 48 hours).     Discussion Top Abstract Introduction Materials and methods Results Discussion References In the present study, we investigated the effects of the NF-B inhibitor SN50 on MM cell lines and patient cells, as well as on normal B lymphocytes. We found that SN50 inhibited constitutive and induced NF-B activity and induced apoptosis in MM cell lines and patient cells, including those resistant to conventional therapies, but not in normal human B lymphocytes. SN50 down-regulated Bcl-2, A1, XIAP, cIAP-1, cIAP-2, and survivin protein levels, up-regulated Bax expression, induced release of mitochondrial cytochrome c into the cytoplasm, and activated caspase-9 and caspase-3 but not caspase-8. SN50 also sensitized MM cells to TNF- and doxorubicin and had a synergistic proapoptotic effect with a p38 inhibitor. These studies provide the framework for targeting NF-B in MM therapies. Several established or novel anti-MM agents, such as dexamethasone, thalidomide, proteasome inhibitors, and arsenic trioxide, have the ability to inhibit NF-B activation.21-26 As a consequence, NF-B inhibition may be at least a component of their antitumor activity. However, the exact contribution of NF-B inhibition to their anti-MM activity has not been delineated. Moreover, the effect of specific NF-B inhibition on MM cells is also unknown. We therefore used an inhibitor of the nuclear translocation of NF-B to characterize the role of this transcription factor in MM cells.29 We found that the NF-B inhibitor SN50 induced apoptosis in most MM cell lines, as well as in primary patient cells, but not in normal B lymphocytes. In previous studies of our panel of cell lines, the 2 SN50-resistant cell lines constitutively express the highest levels of various apoptosis inhibitors, including FLICE/caspase-8 inhibitory protein (FLIP), cIAP-1, cIAP-2, XIAP, and survivin.40 We then investigated the molecular mechanism of SN50-induced MM cell apoptosis. We found evidence of mitochondrial involvement, including Bcl-2 and A1 down-regulation, release of mitochondrial cytochrome c to the cytoplasm, and activation of caspase-9. Several members of the Bcl-2 family of apoptosis inhibitors are regulated by Rel/NF-B transcription factors in various models, including Bcl-2 and A1.44-49 On the other hand, mitogen-activated B cells from mice lacking c-Rel or p50 expression are very sensitive to apoptosis and can be rescued by overexpression of Bcl-213 or A1.48 Moreover, A1 regulates the survival of macrophages in an NF-B-dependent fashion by preserving mitochondrial integrity50 and suppresses apoptosis by inhibiting cytochrome c release and caspase-3 activation.44 In our model, the increase in Bax and the decrease in Bcl-2 and A1 protein levels shift the balance of Bcl2-A1/Bax toward apoptosis. Bax induces pore formation in the mitochondrial membrane and ultimately facilitates the release of cytochrome c into the cytoplasm,51 as in the present study. Cytochrome c binds the adaptor molecule Apaf-1 and forms the "apoptosome" that activates caspase-9, which cleaves and activates caspase-3.52,53 The role of caspase-9 and caspase-3 in our model is confirmed, since specific caspase-3 and caspase-9 inhibitors attenuated SN50-induced apoptosis. The apoptosis inhibitor XIAP is NF-B dependent in other models.35,54 Since XIAP inhibits caspase-9 activity, it appears that NF-B inhibition stimulates caspase-9-dependent apoptosis in a dual manner: by stimulating the release of mitochondrial cytochrome c, leading to the formation of the apoptosome; and by down-regulating XIAP expression. Activated caspase-9 then activates caspase-3. In our study, the expression of survivin, another member of the IAP family, was also found to be NF-B dependent in MM cells. Since caspase-3 can be inhibited by survivin,55 it appears that NF-B also regulates MM cell apoptosis at the level of caspase-3 activity. We recently demonstrated that TNF- is secreted into the bone marrow microenvironment by MM cells and induces NF-B-dependent alterations in adhesion molecule expression on both MM cells and bone marrow stromal cells, with resulting increased cell adhesion. This binding confers resistance to apoptosis and also triggers NF-B-dependent secretion of IL-6. TNF- also causes a modest, but reproducible, MM cell proliferation.27 In this study, we investigated the effect of NF-B inhibition on the sequelae of TNF- on MM.1S cells. In contrast to the moderate (approximately 25% increased) proliferation response to TNF- monotherapy, TNF- also induced a moderate reduction of survival (approximately 25% decrease) via activation of caspase-8 and caspase-3 when combined with a noncytotoxic concentration of SN50. These data suggest that TNF- is not per se a growth factor for MM cells, but is rather a proapoptotic factor that activates caspase-8 and caspase-3. Our data further suggest that constitutive activity of NF-B in MM cells abrogates the proapoptotic effect of TNF-, owing to the potent up-regulation of cIAP-1 and cIAP-2, and induces modest proliferation. We have also recently reported that NF-B inhibition increases the sensitivity of MM cells to another member of the TNF family, TRAIL/Apo2L.56 As was observed in this study, this sensitizing effect is associated with down-regulation of cIAP-1 and cIAP-2, members of the IAP family of antiapoptotic proteins that are recruited to the signaling complex of TNF receptor I via their interaction with TNF-receptor-associated factor 1 (TRAF1) and TRAF2, thereby exerting an inhibitory function on caspase-8 activation.57 The expression of cIAP-2 is also regulated by NF-B in human leukemic cells.58 Moreover, overexpression of cIAP-1 and cIAP-2 can protect RelA-deficient cells, which are highly sensitive to TNF--induced apoptosis, by blocking the activation of caspase-8.57 Thus, cIAP-1 and/or cIAP-2 mediate, at least in part, the protective effect of NF-B against apoptosis in MM cells. These data collectively demonstrate a dual antiapoptotic effect of NF-B in MM cells: first, at the level of caspase-8 in the death-receptor pathway and second, at the mitochondrial level. Our work further suggests that the death-receptor pathway is more sensitive to NF-B inhibition, since lower concentrations of SN50 are sufficient to potentiate death-receptor-induced apoptosis in our model, in both this and prior studies.40 In contrast, mitochondrial dysfunction apparently requires complete abrogation of constitutive NF-B activity. It is possible that this dual regulation corresponds to different conditions in vivo: complete abrogation of NF-B activity may by itself be sufficient to induce MM cell apoptosis, whereas a partial block in NF-B activity may require an extracellular stimulus in the form of a death ligand, such as TNF- or TRAIL/Apo2L, to efficiently trigger cell death. NF-B confers protection against apoptosis induced by chemotherapy in several types of cells,44,57 and numerous tumor cells with elevated levels of NF-B are resistant to apoptosis induced by chemotherapy and radiotherapy. Conversely, adenoviral delivery of a superrepressor form of IB sensitizes chemoresistant tumors to TNF- and to the chemotherapeutic drug CPT-11, leading to tumor regression.59 In addition, proteasome inhibitors, such as PS-341, inhibit NF-B by blocking the degradation of IB, thereby increasing their sensitivity to doxorubicin.60 In this study, we similarly detected a potent sensitizing effect of SN50 on doxorubicin-induced apoptosis in MM cells, as well as more modest increments in apoptosis induced by the proteasome inhibitor PS-341 and dexamethasone. Finally, SN50 had a synergistic proapoptotic effect with p38 inhibition, suggesting cross-talk between these 2 signaling pathways in MM cells. In summary, we have demonstrated that NF-B protects MM cells from apoptosis both by maintaining mitochondrial stability via the expression of Bcl-2 and A1 and by attenuating death-receptor-induced apoptosis via the expression of cIAP-1 and cIAP-2. These studies delineate the role of NF-B as an antiapoptotic factor in MM cells and suggest the potential utility of combining novel agents targeting NF-B with standard anti-MM chemotherapeutics.     Footnotes Submitted October 22, 2001; accepted December 20, 2001. Supported by the Multiple Myeloma Research Foundation (N.M., C.S.M.); the Laurie Strauss Leukemia Foundation (N.M., C.S.M.); the Bailey Family Research Fund (N.M., C.S.M.); a National Institutes of Health Career Development Award (S.P.T.); and the Doris Duke Distinguished Clinical Research Scientist Award (K.C.A.). The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Kenneth C. Anderson, Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: kenneth_anderson{at}dfci.harvard.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21[Free Full Text]. 2. Treon SP, Mollick JA, Urashima M, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999;93:1287-1298[Abstract/Free Full Text]. 3. Anderson K. Advances in the biology of multiple myeloma: therapeutic applications. Semin Oncol. 1999;26:10-22[Medline] [Order article via Infotrieve]. 4. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657-1664[Free Full Text]. 5. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene. 1999;18:6842-6844[CrossRef][Medline] [Order article via Infotrieve]. 6. Bendall HH, Sikes ML, Ballard DW, Oltz EM. An intact NF-kappa B signaling pathway is required for maintenance of mature B cell subsets. Mol Immunol. 1999;36:187-195[CrossRef][Medline] [Order article via Infotrieve]. 7. Doerre S, Corley RB. Constitutive nuclear translocation of NF-kappa B in B cells in the absence of I kappa B degradation. J Immunol. 1999;163:269-277[Abstract/Free Full Text]. 8. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-kappa B activity in neurons. Mol Cell Biol. 1994;14:3981-3992[Abstract/Free Full Text]. 9. Korner M, Tarantino N, Debre P. Constitutive activation of NF-kB in human thymocytes. Biochem Biophys Res Commun. 1991;181:80-86[CrossRef][Medline] [Order article via Infotrieve]. 10. Delfino F, Walker WH. Stage-specific nuclear expression of NF-kappaB in mammalian testis. Mol Endocrinol. 1998;12:1696-1707[Abstract/Free Full Text]. 11. Krishnamoorthy RR, Crawford MJ, Chaturvedi MM, et al. Photo-oxidative stress down-modulates the activity of nuclear factor-kappaB via involvement of caspase-1, leading to apoptosis of photoreceptor cells. J Biol Chem. 1999;274:3734-3743[Abstract/Free Full Text]. 12. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell. 1995;80:321-330[CrossRef][Medline] [Order article via Infotrieve]. 13. Grumont RJ, Rourke IJ, O'Reilly LA, et al. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med. 1998;187:663-674[Abstract/Free Full Text]. 14. Rayet B, Gelinas C. Aberrant Rel/NFkB genes and activity in human cancer. Oncogene. 1999;18:6938-6947[CrossRef][Medline] [Order article via Infotrieve]. 15. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953[CrossRef][Medline] [Order article via Infotrieve]. 16. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18:3063-3070[CrossRef][Medline] [Order article via Infotrieve]. 17. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17:3629-3639[Abstract]. 18. Griffin JD. Leukemia stem cells and constitutive activation of NF-kappaB. Blood. 2001;98:2291a. 19. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307[Abstract/Free Full Text]. 20. Wu M, Lee H, Bellas RE, et al. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 1996;15:4682-4690[Medline] [Order article via Infotrieve]. 21. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290[Abstract/Free Full Text]. 22. Ramdas J, Harmon JM. Glucocorticoid-induced apoptosis and regulation of NF-kappaB activity in human leukemic T cells. Endocrinology. 1998;139:3813-3821[Abstract/Free Full Text]. 23. Wissink S, van Heerde EC, vand der Burg B, van der Saag PT. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. Mol Endocrinol. 1998;12:355-363[Abstract/Free Full Text]. 24. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286[Abstract/Free Full Text]. 25. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: therapeutic implications. Blood. In press. 26. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076[Abstract/Free Full Text]. 27. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527[CrossRef][Medline] [Order article via Infotrieve]. 28. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001;24:263-271[CrossRef][Medline] [Order article via Infotrieve]. 29. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270:14255-14258[Abstract/Free Full Text]. 30. Grundker C, Schulz K, Gunthert AR, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab. 2000;85:3815-3820[Abstract/Free Full Text]. 31. Han YP, Tuan TL, Wu H, Hughes M, Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci. 2001;114:131-139[Abstract]. 32. Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J. Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol. 1999;163:590-598[Abstract/Free Full Text]. 33. Qin ZH, Wang Y, Nakai M, Chase TN. Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum. Mol Pharmacol. 1998;53:33-42[Abstract/Free Full Text]. 34. Qin ZH, Chen RW, Wang Y, Nakai M, Chuang DM, Chase TN. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci. 1999;19:4023-4033[Abstract/Free Full Text]. 35. Xiao C, Ash K, Tsang B. Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor necrosis factor alpha-induced apoptosis. Endocrinology. 2001;142:557-563[Abstract/Free Full Text]. 36. Ye J, Ding M, Zhang X, et al. Induction of TNFalpha in macrophages by vanadate is dependent on activation of transcription factor NF-kappaB and free radical reactions. Mol Cell Biochem. 1999;198:193-200[CrossRef][Medline] [Order article via Infotrieve]. 37. Powers C, Krutzsch H, Gardner K. Modulation of JunD.AP-1 DNA binding activity by AP-1-associated factor1 (AF-1). J Biol Chem. 1996;271:30089-30095[Abstract/Free Full Text]. 38. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol. 1998;153:1947-1956[Abstract/Free Full Text]. 39. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res. 2001;61:4864-4872[Abstract/Free Full Text]. 40. Mitsiades N, Mitsiades C, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL/Apo2L)-induced apoptosis in human multiple myeloma cells. Blood. 2002;99:2162-2171[Abstract/Free Full Text]. 41. Nemoto S, Xiang J, Huang S, Lin A. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem. 1998;273:16415-16420[Abstract/Free Full Text]. 42. Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem. 2001;276:18934-18940[Abstract/Free Full Text]. 43. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996;274:784-787[Abstract/Free Full Text]. 44. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999;19:5923-5929[Abstract/Free Full Text]. 45. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE. NF-kB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem. 2001;20:20[Medline] [Order article via Infotrieve]. 46. Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J. 2000;19:6351-6360[CrossRef][Medline] [Order article via Infotrieve]. 47. Tamatani M, Che YH, Matsuzaki H, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem. 1999;274:8531-8538[Abstract/Free Full Text]. 48. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev. 1999;13:400-411[Abstract/Free Full Text]. 49. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 1999;13:382-387[Abstract/Free Full Text]. 50. Pagliari LJ, Perlman H, Liu H, Pope RM. Macrophages require constitutive NF-kappaB activation to maintain A1 expression and mitochondrial homeostasis. Mol Cell Biol. 2000;20:8855-8865[Abstract/Free Full Text]. 51. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95:4997-5002[Abstract/Free Full Text]. 52. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479-489[CrossRef][Medline] [Order article via Infotrieve]. 53. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999;274:11549-11556[Abstract/Free Full Text]. 54. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked IAP gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med. 1998;188:211-216[Abstract/Free Full Text]. 55. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117-1123[CrossRef][Medline] [Order article via Infotrieve]. 56. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001;98:795-804[Abstract/Free Full Text]. 57. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680-1683[Abstract/Free Full Text]. 58. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A. 1997;94:10057-10062[Abstract/Free Full Text]. 59. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999;5:412-417[CrossRef][Medline] [Order article via Infotrieve]. 60. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood. 1998;91:4624-4631[Abstract/Free Full Text]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. IIJIMA, I. MOMOSE, and D. IKEDA TP-110, a New Proteasome Inhibitor, Down-regulates IAPs in Human Multiple Myeloma Cells Anticancer Res, April 1, 2009; 29(4): 977 - 985. [Abstract] [Full Text] [PDF] S. Sharma and A. Lichtenstein Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors Blood, August 15, 2008; 112(4): 1338 - 1345. [Abstract] [Full Text] [PDF] S. Markovina, N. S. Callander, S. L. O'Connor, J. Kim, J. E. Werndli, M. Raschko, C. P. Leith, B. S. Kahl, K. Kim, and S. Miyamoto Bortezomib-Resistant Nuclear Factor-{kappa}B Activity in Multiple Myeloma Cells Mol. Cancer Res., August 1, 2008; 6(8): 1356 - 1364. [Abstract] [Full Text] [PDF] H. Gu, X. Chen, G. Gao, and H. Dong Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells Mol. Cancer Ther., August 1, 2008; 7(8): 2298 - 2307. [Abstract] [Full Text] [PDF] Y. Xu, F. Fang, D. K. St. Clair, P. Sompol, S. Josson, and W. H. St. Clair SN52, a novel nuclear factor-{kappa}B inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation Mol. Cancer Ther., August 1, 2008; 7(8): 2367 - 2376. [Abstract] [Full Text] [PDF] C. S. Mitsiades, E. M. Ocio, A. Pandiella, P. Maiso, C. Gajate, M. Garayoa, D. Vilanova, J. C. Montero, N. Mitsiades, C. J. McMullan, et al. Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo Cancer Res., July 1, 2008; 68(13): 5216 - 5225. [Abstract] [Full Text] [PDF] J. Song, T. So, and M. Croft Activation of NF-{kappa}B1 by OX40 Contributes to Antigen-Driven T Cell Expansion and Survival J. Immunol., June 1, 2008; 180(11): 7240 - 7248. [Abstract] [Full Text] [PDF] X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia Blood, May 15, 2008; 111(10): 5068 - 5077. [Abstract] [Full Text] [PDF] R. Z. Orlowski and D. J. Kuhn Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657. [Abstract] [Full Text] [PDF] W. Bensinger Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492. [Abstract] [Full Text] [PDF] M. Romagnoli, G. Desplanques, S. Maiga, S. Legouill, M. Dreano, R. Bataille, and S. Barille-Nion Canonical Nuclear Factor {kappa}B Pathway Inhibition Blocks Myeloma Cell Growth and Induces Apoptosis in Strong Synergy with TRAIL Clin. Cancer Res., October 15, 2007; 13(20): 6010 - 6018. [Abstract] [Full Text] [PDF] R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF] R. Kaneko, N. Tsuji, K. Asanuma, H. Tanabe, D. Kobayashi, and N. Watanabe Survivin Down-regulation Plays a Crucial Role in 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor-induced Apoptosis in Cancer J. Biol. Chem., July 6, 2007; 282(27): 19273 - 19281. [Abstract] [Full Text] [PDF] N. J. Bahlis, A. M. King, D. Kolonias, L. M. Carlson, H. Y. Liu, M. A. Hussein, H. R. Terebelo, G. E. Byrne Jr, B. L. Levine, L. H. Boise, et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival Blood, June 1, 2007; 109(11): 5002 - 5010. [Abstract] [Full Text] [PDF] J. R. Berenson, J. Matous, R. A. Swift, R. Mapes, B. Morrison, and H. S. Yeh A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Clin. Cancer Res., March 15, 2007; 13(6): 1762 - 1768. [Abstract] [Full Text] [PDF] S. Meister, U. Schubert, K. Neubert, K. Herrmann, R. Burger, M. Gramatzki, S. Hahn, S. Schreiber, S. Wilhelm, M. Herrmann, et al. Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition Cancer Res., February 15, 2007; 67(4): 1783 - 1792. [Abstract] [Full Text] [PDF] D. Chauhan, P. Neri, M. Velankar, K. Podar, T. Hideshima, M. Fulciniti, P. Tassone, N. Raje, C. Mitsiades, N. Mitsiades, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) Blood, February 1, 2007; 109(3): 1220 - 1227. [Abstract] [Full Text] [PDF] C. S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K. B. Ain, and N. Mitsiades Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4013 - 4021. [Abstract] [Full Text] [PDF] T. Hideshima, P. Neri, P. Tassone, H. Yasui, K. Ishitsuka, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, L. Dang, et al. MLN120B, a Novel I{kappa}B Kinase {beta} Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clin. Cancer Res., October 1, 2006; 12(19): 5887 - 5894. [Abstract] [Full Text] [PDF] P. Dikshit, M. Chatterjee, A. Goswami, A. Mishra, and N. R. Jana Aspirin Induces Apoptosis through the Inhibition of Proteasome Function J. Biol. Chem., September 29, 2006; 281(39): 29228 - 29235. [Abstract] [Full Text] [PDF] C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF] E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr, K. P. Lee, and L. H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood, June 15, 2006; 107(12): 4907 - 4916. [Abstract] [Full Text] [PDF] S. Olivier, P. Close, E. Castermans, L. de Leval, S. Tabruyn, A. Chariot, M. Malaise, M.-P. Merville, V. Bours, and N. Franchimont Raloxifene-Induced Myeloma Cell Apoptosis: A Study of Nuclear Factor-{kappa}B Inhibition and Gene Expression Signature Mol. Pharmacol., May 1, 2006; 69(5): 1615 - 1623. [Abstract] [Full Text] [PDF] B. Blanco, J. A. Perez-Simon, L. I. Sanchez-Abarca, X. Carvajal-Vergara, J. Mateos, B. Vidriales, N. Lopez-Holgado, P. Maiso, M. Alberca, E. Villaron, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines Blood, May 1, 2006; 107(9): 3575 - 3583. [Abstract] [Full Text] [PDF] C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, A. L. Kung, F. E. Davies, G. Morgan, M. Akiyama, R. Shringarpure, N. C. Munshi, et al. Antimyeloma activity of heat shock protein-90 inhibition Blood, February 1, 2006; 107(3): 1092 - 1100. [Abstract] [Full Text] [PDF] M. Z. Dewan, J.-n. Uchihara, K. Terashima, M. Honda, T. Sata, M. Ito, N. Fujii, K. Uozumi, K. Tsukasaki, M. Tomonaga, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir Blood, January 15, 2006; 107(2): 716 - 724. [Abstract] [Full Text] [PDF] Y. Fernandez, T. P. Miller, C. Denoyelle, J. A. Esteban, W.-H. Tang, A. L. Bengston, and M. S. Soengas Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: IMPACT ON TUMOR CELL DEATH J. Biol. Chem., January 13, 2006; 281(2): 1107 - 1118. [Abstract] [Full Text] [PDF] G. Dasmahapatra, M. Rahmani, P. Dent, and S. Grant The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism Blood, January 1, 2006; 107(1): 232 - 240. [Abstract] [Full Text] [PDF] E. David, S.-Y. Sun, E. K. Waller, J. Chen, F. R. Khuri, and S. Lonial The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT Blood, December 15, 2005; 106(13): 4322 - 4329. [Abstract] [Full Text] [PDF] M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-{kappa}B, as a strategy for chemoprevention and therapy of adult T-cell leukemia Blood, October 1, 2005; 106(7): 2462 - 2471. [Abstract] [Full Text] [PDF] T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF] K. Ishitsuka, T. Hideshima, M. Hamasaki, N. Raje, S. Kumar, H. Hideshima, N. Shiraishi, H. Yasui, A. M. Roccaro, P. Richardson, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis Blood, September 1, 2005; 106(5): 1794 - 1800. [Abstract] [Full Text] [PDF] T. Nakazato, K. Ito, Y. Ikeda, and M. Kizaki Green Tea Component, Catechin, Induces Apoptosis of Human Malignant B Cells via Production of Reactive Oxygen Species Clin. Cancer Res., August 15, 2005; 11(16): 6040 - 6049. [Abstract] [Full Text] [PDF] H. Tatetsu, Y. Okuno, M. Nakamura, F. Matsuno, T. Sonoki, I. Taniguchi, S. Uneda, K. Umezawa, H. Mitsuya, and H. Hata Dehydroxymethylepoxyquinomicin, a novel nuclear factor-{kappa}B inhibitor, induces apoptosis in multiple myeloma cells in an I{kappa}B{alpha}-independent manner Mol. Cancer Ther., July 1, 2005; 4(7): 1114 - 1120. [Abstract] [Full Text] [PDF] P. H. Tan, P. Sagoo, C. Chan, J. B. Yates, J. Campbell, S. C. Beutelspacher, B. M. J. Foxwell, G. Lombardi, and A. J. T. George Inhibition of NF-{kappa}B and Oxidative Pathways in Human Dendritic Cells by Antioxidative Vitamins Generates Regulatory T Cells J. Immunol., June 15, 2005; 174(12): 7633 - 7644. [Abstract] [Full Text] [PDF] L. Zhu, G. Somlo, B. Zhou, J. Shao, V. Bedell, M. L. Slovak, X. Liu, J. Luo, and Y. Yen Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma Mol. Cancer Ther., May 1, 2005; 4(5): 787 - 798. [Abstract] [Full Text] [PDF] R. Z. Orlowski, P. M. Voorhees, R. A. Garcia, M. D. Hall, F. J. Kudrik, T. Allred, A. R. Johri, P. E. Jones, A. Ivanova, H. W. Van Deventer, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood, April 15, 2005; 105(8): 3058 - 3065. [Abstract] [Full Text] [PDF] Z. Ma, K.-i. Otsuyama, S. Liu, S. Abroun, H. Ishikawa, N. Tsuyama, M. Obata, F.-J. Li, X. Zheng, Y. Maki, et al. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells Blood, April 15, 2005; 105(8): 3312 - 3318. [Abstract] [Full Text] [PDF] D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson Proteasome inhibitor therapy in multiple myeloma Mol. Cancer Ther., April 1, 2005; 4(4): 686 - 692. [Abstract] [Full Text] [PDF] T. Sanda, S. Iida, H. Ogura, K. Asamitsu, T. Murata, K. B. Bacon, R. Ueda, and T. Okamoto Growth Inhibition of Multiple Myeloma Cells by a Novel I{kappa}B Kinase Inhibitor Clin. Cancer Res., March 1, 2005; 11(5): 1974 - 1982. [Abstract] [Full Text] [PDF] R. Piva, P. Gianferretti, A. Ciucci, R. Taulli, G. Belardo, and M. G. Santoro 15-Deoxy-{Delta}12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-{kappa}B activity and down-regulation of antiapoptotic proteins Blood, February 15, 2005; 105(4): 1750 - 1758. [Abstract] [Full Text] [PDF] S. V. Rajkumar, P. G. Richardson, T. Hideshima, and K. C. Anderson Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer J. Clin. Oncol., January 20, 2005; 23(3): 630 - 639. [Abstract] [Full Text] [PDF] V. Poulaki, C. S. Mitsiades, C. McMullan, G. Fanourakis, J. Negri, A. Goudopoulou, I. X. Halikias, G. Voutsinas, S. Tseleni-Balafouta, J. W. Miller, et al. Human Retinoblastoma Cells Are Resistant to Apoptosis Induced by Death Receptors: Role of Caspase-8 Gene Silencing Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 358 - 366. [Abstract] [Full Text] [PDF] X.-Y. Pei, Y. Dai, and S. Grant The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism Mol. Cancer Ther., December 1, 2004; 3(12): 1513 - 1524. [Abstract] [Full Text] [PDF] N. Parquet, R. Nimmanapalli, C. Anasetti, M. Alsina, W. Dalton, and L. E. Perez Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR). Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2459 - 2459. [Abstract] [Full Text] G. Zauli, E. Rimondi, V. Nicolin, E. Melloni, C. Celeghini, and P. Secchiero TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF Blood, October 1, 2004; 104(7): 2044 - 2050. [Abstract] [Full Text] [PDF] J.-H. Jang and Y.-J. Surh Bcl-2 Attenuation of Oxidative Cell Death Is Associated with Up-regulation of {gamma}-Glutamylcysteine Ligase via Constitutive NF-{kappa}B Activation J. Biol. Chem., September 10, 2004; 279(37): 38779 - 38786. [Abstract] [Full Text] [PDF] S. V. Rajkumar Thalidomide: Tragic Past and Promising Future Mayo Clin. Proc., July 1, 2004; 79(7): 899 - 903. [PDF] M.-T. Lin, C.-C. Chang, S.-T. Chen, H.-L. Chang, J.-L. Su, Y.-P. Chau, and M.-L. Kuo Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-{kappa}B-dependent XIAP Up-Regulation J. Biol. Chem., June 4, 2004; 279(23): 24015 - 24023. [Abstract] [Full Text] [PDF] X.-Y. Pei, Y. Dai, and S. Grant Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors Clin. Cancer Res., June 1, 2004; 10(11): 3839 - 3852. [Abstract] [Full Text] [PDF] Y. Nefedova, P. Cheng, M. Alsina, W. S. Dalton, and D. I. Gabrilovich Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines Blood, May 1, 2004; 103(9): 3503 - 3510. [Abstract] [Full Text] [PDF] T. Stromberg, A. Dimberg, A. Hammarberg, K. Carlson, A. Osterborg, K. Nilsson, and H. Jernberg-Wiklund Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone Blood, April 15, 2004; 103(8): 3138 - 3147. [Abstract] [Full Text] [PDF] N. V. Gopee, V. J. Johnson, and R. P. Sharma Sodium Selenite-Induced Apoptosis in Murine B-Lymphoma Cells Is Associated with Inhibition of Protein Kinase C-{delta}, Nuclear Factor {kappa}B, and Inhibitor of Apoptosis Protein Toxicol. Sci., April 1, 2004; 78(2): 204 - 214. [Abstract] [Full Text] [PDF] Y. Dai, X.-Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant Interruption of the NF-{kappa}B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells Blood, April 1, 2004; 103(7): 2761 - 2770. [Abstract] [Full Text] [PDF] N. R. Jana, P. Dikshit, A. Goswami, and N. Nukina Inhibition of Proteasomal Function by Curcumin Induces Apoptosis through Mitochondrial Pathway J. Biol. Chem., March 19, 2004; 279(12): 11680 - 11685. [Abstract] [Full Text] [PDF] M. A. Guthridge, E. F. Barry, F. A. Felquer, B. J. McClure, F. C. Stomski, H. Ramshaw, and A. F. Lopez The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-{kappa}B and induction of bcl-2 Blood, February 1, 2004; 103(3): 820 - 827. [Abstract] [Full Text] [PDF] C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications PNAS, January 13, 2004; 101(2): 540 - 545. [Abstract] [Full Text] [PDF] J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson Multiple Myeloma Hematology, January 1, 2004; 2004(1): 237 - 256. [Abstract] [Full Text] [PDF] Q. Wang, X. Wang, and B. M. Evers Induction of cIAP-2 in Human Colon Cancer Cells through PKC{delta}/NF-{kappa}B J. Biol. Chem., December 19, 2003; 278(51): 51091 - 51099. [Abstract] [Full Text] [PDF] T. Hideshima, D. Chauhan, T. Hayashi, K. Podar, M. Akiyama, C. Mitsiades, N. MItsiades, B. Gong, L. Bonham, P. de Vries, et al. Antitumor Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitors, a Novel Class of Agents, in Multiple Myeloma Cancer Res., December 1, 2003; 63(23): 8428 - 8436. [Abstract] [Full Text] [PDF] V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398. [Abstract] [Full Text] [PDF] C. S. Mitsiades, N. S. Mitsiades, R. T. Bronson, D. Chauhan, N. Munshi, S. P. Treon, C. A. Maxwell, L. Pilarski, T. Hideshima, R. M. Hoffman, et al. Fluorescence Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/NOD in Vivo Model: Biologic and Clinical Implications Cancer Res., October 15, 2003; 63(20): 6689 - 6696. [Abstract] [Full Text] [PDF] J. C. Pahler, S. Ruiz, I. Niemer, L. R. Calvert, M. Andreeff, M. Keating, S. Faderl, and D. J. McConkey Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia Clin. Cancer Res., October 1, 2003; 9(12): 4570 - 4577. [Abstract] [Full Text] [PDF] P. G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, et al. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma N. Engl. J. Med., June 26, 2003; 348(26): 2609 - 2617. [Abstract] [Full Text] [PDF] L. F. Zerbini, Y. Wang, J.-Y. Cho, and T. A Libermann Constitutive Activation of Nuclear Factor {kappa}B p50/p65 and Fra-1 and JunD Is Essential for Deregulated Interleukin 6 Expression in Prostate Cancer Cancer Res., May 1, 2003; 63(9): 2206 - 2215. [Abstract] [Full Text] [PDF] Y.-T. Tai, K. Podar, N. Mitsiades, B. Lin, C. Mitsiades, D. Gupta, M. Akiyama, L. Catley, T. Hideshima, N. C. Munshi, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling Blood, April 1, 2003; 101(7): 2762 - 2769. [Abstract] [Full Text] [PDF] S. K. Ghosh, C. Wood, L. H. Boise, A. M. Mian, V. V. Deyev, G. Feuer, N. L. Toomey, N. C. Shank, L. Cabral, G. N. Barber, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B Blood, March 15, 2003; 101(6): 2321 - 2327. [Abstract] [Full Text] [PDF] N. Mitsiades, C. S. Mitsiades, P. G. Richardson, V. Poulaki, Y.-T. Tai, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood, March 15, 2003; 101(6): 2377 - 2380. [Abstract] [Full Text] [PDF] F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF] J. F. Garcia, F. I. Camacho, M. Morente, M. Fraga, C. Montalban, T. A. C. Bellas, A. Castano, A. Diez, T. Flores, C. Martin, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays Blood, January 15, 2003; 101(2): 681 - 689. [Abstract] [Full Text] [PDF] M. Akiyama, T. Hideshima, T. Hayashi, Y.-T. Tai, C. S. Mitsiades, N. Mitsiades, D. Chauhan, P. Richardson, N. C. Munshi, and K. C. Anderson Nuclear Factor-{kappa}B p65 Mediates Tumor Necrosis Factor {alpha}-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein Cancer Res., January 1, 2003; 63(1): 18 - 21. [Abstract] [Full Text] [PDF] J. Ursini-Siegel, W. Zhang, A. Altmeyer, E. N. Hatada, R. K. G. Do, H. Yagita, and S. Chen-Kiang TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis J. Immunol., November 15, 2002; 169(10): 5505 - 5513. [Abstract] [Full Text] [PDF] N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, T. A. Libermann, S. P. Treon, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells PNAS, October 29, 2002; 99(22): 14374 - 14379. [Abstract] [Full Text] [PDF] G Pratt Molecular aspects of multiple myeloma Mol. Pathol., October 1, 2002; 55(5): 273 - 283. [Abstract] [Full Text] [PDF] R. LeBlanc, L. P. Catley, T. Hideshima, S. Lentzsch, C. S. Mitsiades, N. Mitsiades, D. Neuberg, O. Goloubeva, C. S. Pien, J. Adams, et al. Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model Cancer Res., September 1, 2002; 62(17): 4996 - 5000. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mitsiades, N. Articles by Anderson, K. C. Search for Related Content PubMed PubMed Citation Articles by Mitsiades, N. Articles by Anderson, K. C. Related Collections Neoplasia Signal Transduction Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020